Aberdeen Group plc Grows Position in ProQR Therapeutics N.V. $PRQR

Aberdeen Group plc increased its position in ProQR Therapeutics N.V. (NASDAQ:PRQR) by 24.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,298,823 shares of the biopharmaceutical company’s stock after buying an additional 448,475 shares during the quarter. Aberdeen Group plc owned about 2.18% of ProQR Therapeutics worth $4,896,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Osaic Holdings Inc. boosted its holdings in ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares during the period. Jane Street Group LLC boosted its holdings in shares of ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 79,720 shares during the period. Bank of America Corp DE raised its position in shares of ProQR Therapeutics by 25.7% during the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 24,347 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of ProQR Therapeutics by 28.4% during the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 26,893 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of ProQR Therapeutics by 5.6% in the second quarter. Walleye Capital LLC now owns 531,977 shares of the biopharmaceutical company’s stock valued at $1,085,000 after purchasing an additional 28,413 shares during the period. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Trading Down 2.0%

Shares of NASDAQ:PRQR opened at $1.44 on Friday. The stock has a market capitalization of $151.50 million, a PE ratio of -3.06 and a beta of 0.20. The firm has a fifty day moving average price of $1.79 and a 200 day moving average price of $2.11. ProQR Therapeutics N.V. has a 1 year low of $1.07 and a 1 year high of $3.10.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Chardan Capital restated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research report on Tuesday, November 4th. Finally, Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.14.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.